ANAB → $90.00 by Oct 12, 2026.

AnaptysBio (ANAB) isn’t your traditional biotech play. Essentially, it is a low-overhead royalty-management company formed around 2 drugs: Jemperli (partnered with GSK) and imsidolimab (partnered with Vanda Pharma). Here’s the relevant backstory. In 2014, ANAB signed a collaboration and exclusive licensing agreement with the biotech company Tesaro, resulting in the development of Jemperli, a blockbuster (>$1B global sales) therapeutic immuno-oncology antibody, currently approved for endometrial cancer. In this deal, ANAB receives tiered royalties that step up with higher sales ([link](https://ir.anaptysbio.com/static-files/d12275b2-d99f-4a2e-8697-de3a6969ec68)). …